Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372073 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Cyclacel Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT00372073: Clinical Trial Phase 2 study, sponsored by Cyclacel Pharmaceuticals.
NCT00372073 is a Phase 2 study that was terminated before completion, run by Cyclacel Pharmaceuticals. The registered enrollment target is 187 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00372073, a Phase 2 study, was terminated before completion, sponsored by Cyclacel Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).
Primary Outcome
Time until the disease starts progressing
Interventions
- DRUG placebo
- DRUG seliciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2006-08-09 |
| Est. Completion | 2009-04-07 |
| Phase | Phase 2 |
Why NCT00372073 stopped before completion
NCT00372073 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00372073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00372073 about?
NCT00372073 is a clinical study titled "Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer". A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00372073?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2006-08-09. Estimated completion is 2009-04-07.
What interventions are being tested in trial NCT00372073?
The interventions under investigation include: placebo (DRUG), seliciclib (DRUG).
Who is sponsoring clinical trial NCT00372073?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00372073's enrollment target sits among peer trials
187 357th of 2000 higher than 1,644 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI